Researchers developed nanoparticle-coated liraglutide that can penetrate the skin, potentially eliminating the need for daily injections in obesity treatment.
Needle-free GLP-1 deliveryNanoparticle-coated liraglutide penetrated skin barriers and produced sustained blood sugar and weight effects in mice
What the researchers found
The researchers built a two-step nanoparticle platform using flash nanocomplexation (FNC) technology. Liraglutide was first encapsulated in nanoparticles formed by tannic acid and aluminum ions held together by coordination and hydrogen bonding. These particles were then coated with positively charged hydroxypropyl trimethylammonium chloride chitosan (HTCC) to boost skin penetration.
The resulting nanoparticles demonstrated superior transdermal penetration compared to unformulated liraglutide, produced durable blood-sugar-lowering effects, and showed long-acting therapeutic efficacy against obesity in a mouse model.
Why it matters
Needle phobia and injection fatigue are real barriers to GLP-1 drug adherence. If liraglutide could be delivered painlessly through the skin, more patients might stick with treatment long-term. This nanoparticle platform could also be adapted for other peptide drugs that currently require injection.
The numbers in context
Two-step FNC nanoparticle platform; TA-Al3+ coordination with HTCC coating; superior transdermal penetration; sustained hypoglycemic effects in mice
How the study worked
This was a laboratory and animal study. The researchers used flash nanocomplexation technology to create nanoparticles encapsulating liraglutide, then tested their ability to penetrate skin barriers and produce therapeutic effects in obese mice. The nanoparticles were characterized for size, charge, and stability, then evaluated for transdermal penetration, blood sugar control, and weight management outcomes.
Who was studied
Mouse model (obesity)
What this study cannot tell us
This is an early-stage animal study using mice, so human skin penetration and efficacy are unproven. The abstract does not report specific numbers for weight loss, blood sugar reduction, or skin penetration rates. Long-term safety of the nanoparticle materials applied to skin is unknown. Scaling from laboratory to clinical manufacturing would require significant additional development.
How to read the evidence
This is a preliminary-evidence animal study. While it demonstrates a promising proof of concept for transdermal liraglutide delivery, results are limited to mouse models with no human data and no specific quantitative outcomes reported in the abstract.
When this study was published
Published in 2025, this is very recent research reflecting current advances in peptide delivery technology.
The bigger picture
The GLP-1 drug market is booming, but nearly all these medications require injections. Multiple research groups are racing to develop needle-free delivery methods — oral pills, skin patches, and transdermal systems. This nanoparticle approach adds to that pipeline by showing that liraglutide can be reformulated to cross the skin barrier, which has historically been one of the hardest challenges in peptide drug delivery.
Questions still open
- Can this nanoparticle system deliver enough liraglutide through human skin to match the therapeutic doses achieved by injection?
- How do the tannic acid and aluminum nanoparticle materials affect skin health with repeated long-term application?
- Could this platform be adapted for newer, more potent GLP-1 drugs like semaglutide or tirzepatide?
Common questions
Could this technology eliminate the need for GLP-1 injections?
What makes delivering peptides through the skin so difficult?
Read the original research
Enhanced Transdermal Delivery of Liraglutide for Sustained Obesity Management.
Langmuir : the ACS journal of surfaces and colloids, 41(19), 12189-12198
Citation
Chen, Nipeng; Zeng, Zhipeng; Chen, Haolin; Liu, Hong; Zhang, Zhihui; Ke, Fangfang; Ji, Xiaoyu; Liu, Lixin; Zhang, Zhen; Chen, Yongming. (2025). Enhanced Transdermal Delivery of Liraglutide for Sustained Obesity Management.. Langmuir : the ACS journal of surfaces and colloids, 41(19), 12189-12198. https://doi.org/10.1021/acs.langmuir.5c00949